Results 101 to 110 of about 27,276 (262)

bihealth/reev-docker-compose: v0.6.0

<h3>Features</h3> <ul> <li>add celery worker and beat containers (<a href="https://www.github.com/bihealth/reev-docker-compose/issues/38">#38</a>) (<a href="https://www.github.com/bihealth/reev-docker-compose/issues/
varfish-bot, Dzmitry Hramyka, Manuel Holtgrewe   +2 more
core   +1 more source

docker-interimage: Running the latest InterIMAGE Linux release in a Docker container with user interface

, 2016
<p>This release can run the latest available release of InterIMAGE for Linux, 1.27, in a Docker container by forwarding a local X11 socket into the container and thereby showing the application's user interface.</p ...
Nüst, Daniel
core   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

torkar/docker-b3: Release with Zenodo doi

, 2020
Docker accompanying paper on ...
Richard Torkar, Francisco Gomes de Oliveira Neto   +1 more
core   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Research on Multi⁃Dimensional Distributed Vulnerability Scanning Technology Based on Docker

Liaoning Shiyou Huagong Daxue xuebao
The current frequent occurrence of cyberspace security incidents has resulted in huge losses to national security and the real economy, demonstrating that the information security threats confronting nations have transcended the traditional concept of ...
Weili KONG, Yang CAO, Cong ZHANG, Changlin YANG, Decheng MENG   +4 more
doaj   +1 more source

osirrc/jass-docker: JASS Docker Image for OSIRRC at SIGIR 2019 (v0.1.1)

, 2019
OSIRRC Docker Image for ...
andrewtrotman, Jimmy Lin, Ryan Clancy
core   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

osirrc/indri-docker: Indri Docker Image for OSIRRC at SIGIR 2019 (v0.2.0)

, 2019
OSIRRC Docker Image for ...
Arthur Câmara, Jimmy Lin, Ryan Clancy, Claudia Hauff   +3 more
core   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source